Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival.
- Resource Type
- Article
- Authors
- Tubben, Alwin; Nienhuis, Hans L.A.; van der Meer, Peter
- Source
- European Journal of Heart Failure. Nov2023, Vol. 25 Issue 11, p2065-2066. 2p.
- Subject
- *HEART failure
*HEART failure patients
*TRANSTHYRETIN
*AMYLOIDOSIS
*CARDIOMYOPATHIES
*OVERALL survival
- Language
- ISSN
- 1388-9842
This article discusses the use of tafamidis, a disease-modifying therapy, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM) in patients with severe heart failure symptoms. The article highlights the results of a study that compared the long-term survival of patients with NYHA class III heart failure who were treated with tafamidis versus placebo. The study found that patients who received continuous tafamidis treatment had a lower mortality rate compared to those who received placebo. However, the study did not provide information on cardiovascular-related hospitalizations or quality of life. The article suggests that further research is needed to determine the optimal treatment strategy for patients with severe heart failure symptoms. [Extracted from the article]